首页 | 本学科首页   官方微博 | 高级检索  
     

Cholangiocarcinoma and liver transplantation: What we know so far?
摘    要:

收稿时间:2021-03-03

Cholangiocarcinoma and liver transplantation: What we know so far?
Ali Reza Safarpour,Hassan Askari,Farshid Ejtehadi,Asaad Azarnezhad,Ehsan Raeis-Abdollahi,Amir Tajbakhsh,Mohammad Foad Abazari,Firoozeh Tarkesh,Alireza Shamsaeefar,Ramin Niknam,Gholam Reza Sivandzadeh,Kamran Bagheri Lankarani,Fardad Ejtehadi. Cholangiocarcinoma and liver transplantation: What we know so far?[J]. World journal of gastrointestinal pathophysiology, 2021, 12(5): 84-105. DOI: doi:10.4291/wjgp.v12.i5.84
Authors:Ali Reza Safarpour  Hassan Askari  Farshid Ejtehadi  Asaad Azarnezhad  Ehsan Raeis-Abdollahi  Amir Tajbakhsh  Mohammad Foad Abazari  Firoozeh Tarkesh  Alireza Shamsaeefar  Ramin Niknam  Gholam Reza Sivandzadeh  Kamran Bagheri Lankarani  Fardad Ejtehadi
Abstract:Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.
Keywords:Cholangiocarcinoma   Liver transplantation   Primary sclerosing cholangitis   Neoadjuvant chemoradiotherapy
点击此处可从《World journal of gastrointestinal pathophysiology》浏览原始摘要信息
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号